TNFRSF8 and anaplastic large cell lymphoma: At present, the first-line treatment for patients diagnosed with systemic ALCL is represented by CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) standard chemotherapy, but the recurrence of refractory or relapsed disease entailed the use of stem cell transplantation and the FDA approval of four novel single-agent treatments: pralatrexate, a folic acid antagonist, romidepsin and belinostat, two histone deacetylase inhibitors and Brentuximab vedotin, a drug-conjugated monoclonal antibody directed to CD30-expressing cells [37].